Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 7Prostatic Neoplasms 2Liver Neoplasms 2Colorectal Neoplasms 2Neuroendocrine Tumors 1Digestive System Diseases 1Breast Neoplasms 1

Interventions

Irinotecan 6Gemcitabine 5130-nm albumin-bound paclitaxel 5Oxaliplatin 4Fluorouracil 4Capecitabine 4Bevacizumab 4Albumin-Bound Paclitaxel 4napabucasin 3Ocoxin 3Leucovorin 3pembrolizumab 2Sorafenib 2Paclitaxel 2Nivolumab 2Cyclophosphamide 2Cetuximab 2Bupivacaine 2Aspirin 2Ascorbic Acid 2trifluridine tipiracil drug combination 1trametinib 1pralsetinib 1penpulimab 1ozanimod 1linifanib 1hetrombopag 1halofantrine 1guadecitabine 1golotimod 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Digestive System Diseases × gadolinium ethoxybenzyl DTPA × Clear all
NCT02156739 2025-12-22

Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

M.D. Anderson Cancer Center

Phase NA Active not recruiting
100 enrolled
Gastrointestinal

Digestive System Diseases, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡